TuHURA Biosciences (HURA) Income towards Parent Company (2010 - 2012)
TuHURA Biosciences (HURA) posted quarterly Income towards Parent Company of -$7405.0 for Q4 2012, up 62.24% year-over-year from -$4564.2 in Q1 2012, and down 78.22% quarter-over-quarter from -$4155.0 in Q3 2012.
TuHURA Biosciences (HURA) Income towards Parent Company (2010 - 2012) Analysis & Trends
TuHURA Biosciences' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$7405.0 for Q4 2012.
- In Q4 2012, Income towards Parent Company rose 62.24% year-over-year to -$7405.0; the TTM figure through Sep 2013 stood at -$7405.0 (up 85.76% YoY), while the FY2012 annual figure was -$18885.0, up 43.01% from the prior year.
- Income towards Parent Company for Q4 2012 stood at -$7405.0, down from -$4155.0 in the prior quarter.
- The five-year high for Income towards Parent Company was -$3827.0 in Q1 2011, with the low at -$23526.0 in Q1 2012.
- The 3-year median for Income towards Parent Company is -$7118.0 (2011), against an average of -$9641.4.
- Peak annual rise in Income towards Parent Company reached 62.24% in 2012, while the deepest fall reached 514.74% in 2012.
- TuHURA Biosciences' Income towards Parent Company stood at -$14568.0 in 2010, then slumped by 34.62% to -$19612.0 in 2011, then soared by 62.24% to -$7405.0 in 2012.
- Business Quant data shows HURA's Income towards Parent Company at -$7405.0 in Q4 2012, -$4155.0 in Q3 2012, and -$4722.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -7,405.00 |
| Sep 30, 2012 | -4,155.00 |
| Jun 30, 2012 | -4,722.00 |
| Mar 31, 2012 | -23,526.00 |
| Dec 31, 2011 | -19,612.00 |
| Sep 30, 2011 | -3,858.00 |
| Jun 30, 2011 | -6,831.00 |
| Mar 31, 2011 | -3,827.00 |
| Dec 31, 2010 | -14,568.00 |
| Sep 30, 2010 | -7,910.00 |